- Trials with a EudraCT protocol (47)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
47 result(s) found for: Cerebral atrophy.
Displaying page 1 of 3.
EudraCT Number: 2014-002118-21 | Sponsor Protocol Number: CPZOL | Start Date*: 2017-03-17 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Randers Regional Hospital | ||||||||||||||||||||||||||||||||||||||
Full Title: Zoledronate against fractures in children with cerebral palsy | ||||||||||||||||||||||||||||||||||||||
Medical condition: cerebral palsy, osteopenia, fracture | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002295-40 | Sponsor Protocol Number: 08-06-2018-paracet | Start Date*: 2018-09-11 |
Sponsor Name:Copenhagen Neuromuscular Center | ||
Full Title: Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy | ||
Medical condition: Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP) | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000956-12 | Sponsor Protocol Number: 277HV101 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previou... | |||||||||||||
Medical condition: Spinal muscular atrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Ongoing) PT (Prematurely Ended) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004634-41 | Sponsor Protocol Number: IIBSP-FPI-2019-108 | Start Date*: 2021-08-25 |
Sponsor Name:Institut de Recerca HSCSP | ||
Full Title: Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome | ||
Medical condition: Taupathies | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001949-42 | Sponsor Protocol Number: BRD50 | Start Date*: 2005-09-08 |
Sponsor Name:University College London | ||
Full Title: A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-018157-23 | Sponsor Protocol Number: D0490C00014 | Start Date*: 2010-11-30 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ... | |||||||||||||
Medical condition: Multiple system atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000928-18 | Sponsor Protocol Number: PROMESA | Start Date*: 2013-11-21 |
Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich | ||
Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr... | ||
Medical condition: Progression of patients with Multiple System Atrophy (MSA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003284-38 | Sponsor Protocol Number: EVG001SAH | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Evgen Pharma plc | |||||||||||||
Full Title: SFX-01 AFTER SUBARACHNOID HAEMORRHAGE | |||||||||||||
Medical condition: Subarachnoid Haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000621-12 | Sponsor Protocol Number: ISIS396443-CS3A | Start Date*: 2017-02-15 |
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||
Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy | ||
Medical condition: Spinal Muscular Atrophy (SMA) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-002805-13 | Sponsor Protocol Number: LTF-304 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:bluebird bio, Inc | |||||||||||||
Full Title: Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product | |||||||||||||
Medical condition: Cerebral Adrenoleukodystrophy (CALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003008-30 | Sponsor Protocol Number: 16/0730 | Start Date*: 2020-07-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage | |||||||||||||
Medical condition: Multiple Sclerosis (Secondary Progressive) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001953-10 | Sponsor Protocol Number: ALD-102 | Start Date*: 2013-12-13 | |||||||||||
Sponsor Name:bluebird bio, Inc. | |||||||||||||
Full Title: A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD) | |||||||||||||
Medical condition: Cerebral Adrenoleukodystrophy (CALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003484-30 | Sponsor Protocol Number: CFTY720DES03 | Start Date*: 2011-10-26 |
Sponsor Name:Novartis Farmacéutica S.A. | ||
Full Title: A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or... | ||
Medical condition: Multiple Sclerosis relapsing-remitting course | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005262-39 | Sponsor Protocol Number: 2006-2209 | Start Date*: 2007-05-30 |
Sponsor Name:Charité-Universitätsmedizin Berlin | ||
Full Title: Flupirtin as Oral Treatment in MS | ||
Medical condition: Relapsing-remitting multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004733-17 | Sponsor Protocol Number: XAMNPEAP2019 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Aurora Pujol Onofre | |||||||||||||
Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial | |||||||||||||
Medical condition: Adrenomyeloneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012569-79 | Sponsor Protocol Number: BAY94-9172/14595 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when com... | |||||||||||||
Medical condition: Detection/Exclusion of cerebral ß-amyloid. To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000654-59 | Sponsor Protocol Number: MT-2-02 | Start Date*: 2019-06-25 | |||||||||||
Sponsor Name:Minoryx Therapeutics S.L. | |||||||||||||
Full Title: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral... | |||||||||||||
Medical condition: Cerebral X-linked Adrenoleukodystrophy (cALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001145-14 | Sponsor Protocol Number: ALD-104 | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:bluebird bio, Inc. | |||||||||||||
Full Title: A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) | |||||||||||||
Medical condition: Cerebral Adrenoleukodystrophy (CALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000422-38 | Sponsor Protocol Number: PET_imaging_of_Tau | Start Date*: 2014-09-19 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Skåne University Hospital, Region Skåne | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002256-42 | Sponsor Protocol Number: 311741 | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/excl... | |||||||||||||
Medical condition: Probable Alzheimer Disease patients compared to Healthy Volunteers. The clinical diagnosis - in Part A made by the investigator, in Part B established by an independent consensus panel of experts... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
